Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302
    Meeting Abstract

    Ricci, D. S.; Li, W. M.; Griffin, T. W.; Gormley, M.; Henitz, E.; Ryan, C. J.; de Bono, J. S.; Attard, G.; Van Den Eertwegh, A. J. M.; Schrijvers, D. L.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment
    Meeting Abstract

    Rathkopf, D. E.; Antonarakis, E. S.; Shore, N. D.; Tutrone, R. F.; Alumkal, J. J.; Ryan, C. J.; Saleh, M. N.; Hauke, R. J.; Bandekar, R.; Maneval, E. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Carver, B. S.; Chen, Y.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Autio, K. A.; DeNunzio, M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT)
    Meeting Abstract

    Powles, T.; Oudard, S.; Escudier, B. J.; Brown, J. E.; Hawkins, R. E.; Castellano, D. E.; Ravaud, A.; Staehler, M. D.; Rini, B. I.; Lin, W.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE)
    Meeting Abstract

    Patel, J. N.; Jiang, C.; Hertz, D. L.; Mulkey, F.; Friedman, P. N.; Halabi, S.; Ratain, M. J.; Morris, M. J.; Small, E. J.; Owzar, K.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Minibody imaging of prostate-specific membrane antigen (PSMA): From concept in clinic
    Meeting Abstract

    Olafsen, T.; Bartlett, D.; Ho, D.; Zhang, G.; Torgov, M.; Keppler, J.; Behrenbruch, C.; Wu, A.; Pandit-Taskar, N.; Morris, M. J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial
    Meeting Abstract

    Motzer, R. J.; Rini, B. I.; McDermott, D. F.; Redman, B. G.; Kuzel, T.; Harrison, M. R.; Vaishampayan, U. N.; Drabkin, H. A.; George, S.; Logan, T. F.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo
    Meeting Abstract

    Morris, M. J.; Loriot, Y.; Beer, T. M.; Higano, C. S.; Armstrong, A. J.; Sternberg, C. N.; de Bono, J. S.; Tombal, B. F.; Noonberg, S. B.; Mansbach, H. H.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), +/- docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results
    Meeting Abstract

    Morris, M. J.; Gleave, M. E.; Armstrong, A. J.; Carducci, M. A.; Saad, F.; Lacuna, K. P.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Female germ cell tumors (GCT): The Memorial Sloan Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Meisel, J. L.; Woo, K.; Sudarsan, N.; Eng, J.; Patil, S.; Jacobsen, E. P.; Murali, R.; Motzer, R. J.; Bosl, G. J.; Aghajanian, C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save